Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | ESRRA | P11474 | 4/20 | 0.47 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.46 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17854916 | 0.92 | FOXM1 (0.48) | SRD5A2ESRRASRD5A1FOXM1ALDH1A1 | |
| SCHEMBL12577906 | 0.89 | SRD5A2 (0.62) | SRD5A2SRD5A1FOXM1ALDH1A1KDM4E | |
| SCHEMBL18002481 | 0.86 | ESRRA (0.43) | SRD5A2ESRRASRD5A1FOXM1ALDH1A1 | |
| SCHEMBL18001514 | 0.85 | NPC1 (0.52) | ESRRASRD5A1ALDH1A1POLBL3MBTL1 | |
| SCHEMBL18003380 | 0.84 | ESRRA (0.41) | SRD5A2ESRRASRD5A1FOXM1ALDH1A1 | |
| SCHEMBL18002615 | 0.84 | ESRRA (0.41) | SRD5A2ESRRASRD5A1FOXM1ALDH1A1 | |
| SCHEMBL2697140 | 0.84 | ESRRA (0.53) | ESRRAALDH1A1POLBL3MBTL1RAB9A | |
| SCHEMBL12577886 | 0.83 | IDO1 (0.52) | SRD5A2FOXM1ALDH1A1KDM4EPOLB | |
| SCHEMBL18003240 | 0.83 | SLC6A4 (0.45) | SRD5A2ESRRASRD5A1FOXM1ALDH1A1 | |
| SCHEMBL17508251 | 0.82 | DDR1 (0.47) | SRD5A2FOXM1ALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040951-A9 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-02-14 | — | — | US | disclosed |
| US-20130040951-A9 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-02-14 | — | — | US | disclosed |
| US-20130040951-A9 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-02-14 | — | — | US | disclosed |
| US-20120196864-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-08-02 | — | — | US | disclosed |
| US-20120196864-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-08-02 | — | — | US | disclosed |
| US-20120196864-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-08-02 | — | — | US | disclosed |
| EP-2450352-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-2450352-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-7977489-B2 | Benzylthiazolone inhibitors of estrogen-related receptors (ERR) | EXELIXIS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| WO-2011016501-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | 武田薬品工業株式会社 (JP) | 2011-02-10 | — | — | WO | disclosed |
| US-20090197870-A1 | Pharmaceutical Compositions | EXELIXIS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| EP-1805154-A2 | PHARMACEUTICAL COMPOSITIONS | Exelixis, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006047269-A2 | PHARMACEUTICAL COMPOSITIONS | EXELIXIS, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040951-A9 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | BRCA1, ESRRA, NR5A1 | SRD5A2 104/4885ESRRA 2/4885SRD5A1 97/4885 |
| US-20120196864-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | BRCA1, ESRRA, NR5A1 | SRD5A2 104/4885ESRRA 2/4885SRD5A1 97/4885 |
| US-20090197870-A1 | Pharmaceutical Compositions | ESRRA, ESRRB, ESR2 | SRD5A2 112/4885ESRRA 1/4885SRD5A1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.